NGM Biopharma: Set to nearly halve as liver disease trial fails

NGM Biopharmaceuticals

24/05/2021 13:03

** Shares of NGM Biopharmaceuticals  NGM.O  plummet 47.2%
premarket to $14.99, set for their worst day on record
    ** Co says its phase 2b study for using aldafermin in
treating non-alcoholic steatohepatitis, a liver disease, did not
meet the primary goal of fibrosis improvement  urn:newsml:reuters.com:*:nFWN2NB0EK
    ** Co plans not to pursue a phase 3 clinical development
    ** Stock set to open at its lowest in eight months, down
6.3% YTD

 (Reporting by Ambar Warrick in Bengaluru)
 ((Ambar.Warrick@thomsonreuters.com; +91-80-6182-2837; Reuters
Messaging: ambar.warrick.thomsonreuters.com@reuters.net;
Twitter: @AmbarWarrick))